Skip to content

Imaging tumor angiogenesis using [18F]-DCFPyL PET/CT in patients with colon, gastric and pancreatic cancer.

Imaging tumor angiogenesis using [18F]-DCFPyL PET/CT in patients with colon, gastric and pancreatic cancer.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON27578
Enrollment
30
Registered
2020-05-02
Start date
2020-05-02
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon, gastric and pancreatic cancer.

Interventions

[18F]DCFPyL PET/CT, [18F]FDG PET/CT scan

Sponsors

LUMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients aged 18 years or older. • Diagnosis of primary T3-4N0-2M0-1 colorectal adenocarcinoma (cohort 1), primary T3-4N0- 2M0 gastric carcinoma (cohort 2), or suspected pancreatic ductal adenocarcinoma (cohort 3) and eligible for surgery. • Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.

Exclusion criteria

Exclusion criteria: • Women who are pregnant and/or or lactating. • Medical or psychiatric conditions that compromise the patient’s ability to give informed consent. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. • Prior radiotherapy to the abdomen (cohort 1, 2 and 3) and/or thorax (cohort 2 and 3). • Unacceptable known (clinically significant) cardiovascular or pulmonary disease, renal or liver dysfunction, which could hamper participation in this study or jeopardize the patients’ health. • Known hypersensitivity to drugs comparative to DCFPYL, or any of their excipients or to any component of [18F]-DCFPYL. • Inability to undergo PET/CT scanning (e.g. claustrophobia, weight limits or inability to tolerate lying for the duration of a PET/CT scan (~30 min). • Inability to undergo routine MRI or CT scans as part of the diagnostic work up.

Design outcomes

Primary

MeasureTime frame
To determine if primary colon, gastric and pancreatic cancer can be detected by [18F]-DCFPYL PET/CT imaging.

Secondary

MeasureTime frame
- Assess agreement between the [18F]-DCFPYL PET/CT-imaging signal in the cancer and histopathologic evidence of cancer and PSMA expression on the resection specimen. - Assess the agreement of [18F]-DCFPYL PET/CT and other preoperative imaging modalities ([18F]-FDG-PET/CT, MR imaging, CT imaging, gastroscopy, colonoscopy).

Contacts

Public ContactFloris Vuijk

Leiden University Medical Center

f.a.vuijk@lumc.nl071-5265130

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)